Investor Presentation Full Year 2021
62
Investor presentation
Full year 2021
In STEP 4, people treated with semaglutide had a superior
weight loss of up to 18.2%
STEP 4 showed significantly greater weight loss post run-in than placebo
% change in
body weight
Randomisation
Data from STEP 4
0
-2
-4
-6
-8
≈ 46%
-10
I
I
Placebo: -5.2%
-12
-10.5%
-14
-16
I
-18
I
Semaglutide: -18.2%
-20
0 4 8 12 16 20 24 28
36
44
52
60
68
88
Time since initiation (weeks)
Change in body weight in % depicts observed means since time of randomisation; trial product estimand; BMI: body mass index
•
•
Average age 46
79% women
Average BMI - 38.4 kg/m²
Novo NordiskⓇ
Trial highlights that obesity is a chronic
disease requiring sustained treatment
Improvements on a panel of
cardiovascular risk markersView entire presentation